PTC Therapeutics, Inc. (PTCT) — Analyst outlook / Analyst consensus target is. Based on 26 analyst ratings, the consensus is bullish — 15 Buy, 9 Hold, 2 Sell.
The consensus price target is $84.50 (low: $50.00, high: $120.00), representing an upside of 15.7% from the current price $73.01.
Analysts estimate Earnings Per Share (EPS) of $-4.45 and revenue of $0.80B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-4.73 vs est $-4.45 (missed -6.2%). 2025: actual $8.58 vs est $9.50 (missed -9.7%). Analyst accuracy: 92%.
PTCT Stock — 12-Month Price Forecast
$84.50
▲ +15.74% Upside
Average Price Target
Based on 26 Wall Street analysts offering 12-month price targets for PTC Therapeutics, Inc., the average price target is $84.50, with a high forecast of $120.00, and a low forecast of $50.00.
The average price target represents a +15.74% change from the last price of $73.01.
Highest Price Target
$120.00
Average Price Target
$84.50
Lowest Price Target
$50.00
PTCT Analyst Ratings
Buy
Based on 26 analysts giving stock ratings to PTC Therapeutics, Inc. in the past 3 months
EPS Estimates — PTCT
92%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$4.73
vs Est –$4.45
▼ 5.8% off
2025
Actual $8.58
vs Est $9.50
▼ 10.7% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — PTCT
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.807B
vs Est $0.804B
▲ 0.4% off
2025
Actual $1.731B
vs Est $1.848B
▼ 6.8% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
